Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients (vol 5, pg 312, 2017)

被引：3
|
作者：
de Velasco, G.
Je, Y.
Bosse, D.
Awad, M. M.
Ott, P. A.
Moreira, R. B.
Schutz, F.
Bellmunt, J.
Sonpavde, G. P.
Hodi, F. S.
Choueiri, T. K.
机构：
来源：
CANCER IMMUNOLOGY RESEARCH | 2018年 / 6卷 / 04期
关键词：
D O I：
10.1158/2326-6066.CIR-18-0078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：498 / 499
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a systematic review and meta-analysis
    Song, Dandan
    Hou, Shufu
    Ma, Ning
    Yan, Bing
    Gao, Jing
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [22] Immune checkpoint therapy: From CTLA-4 to PD-1/PD-L1 and beyond
    Sharma, Padmanee
    CANCER RESEARCH, 2018, 78 (13)
  • [23] Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
    Huang, Shuang
    Zheng, Gang
    Yang, Kai
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [24] Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
    Shuang Huang
    Gang Zheng
    Kai Yang
    World Journal of Surgical Oncology, 21
  • [25] Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
    Zhang, Yixi
    La, Bin
    Liang, Baosheng
    Gu, Yangchun
    LIFE-BASEL, 2021, 11 (11):
  • [26] Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
    Yan, Ting
    Long, Minghui
    Liu, Chaoyi
    Zhang, Jiwen
    Wei, Xingyu
    Li, Fei
    Liao, Dehua
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [27] IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS RECEIVING PD-1/PD-L1 INHIBITORS: PRELIMINARY RESULTS FROM A PROSPECTIVE COHORT STUDY
    Ferrarini, A.
    Benfaremo, D.
    Rossetti, G.
    Morgese, F.
    Tonnini, C.
    Berardi, R.
    Gabrielli, A.
    Pomponio, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1892 - 1893
  • [28] Immune-related adverse events (IRAEs) in metastatic lung cancer patients receiving PD-1/PD-L1 inhibitors and thoracic radiotherapy.
    Hwang, William L.
    Niemierko, Andrzej
    Willers, Henning
    Keane, Florence K.
    Gainor, Justin F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
    Wang, Peng-Fei
    Chen, Yang
    Song, Si-Ying
    Wang, Ting-Jian
    Ji, Wen-Jun
    Li, Shou-Wei
    Liu, Ning
    Yan, Chang-Xiang
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [30] The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis
    Tian, Yuan
    Li, Ran
    Liu, Yan
    Li, Meng
    Song, Yuxiao
    Zheng, Yan
    Gao, Aiqin
    Wen, Qing
    Su, Guohai
    Sun, Yuping
    FRONTIERS IN ONCOLOGY, 2021, 11
12345